Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amicus Therapeutics (FOLD) Tops Q3 EPS by 8c, Revenues Miss; Raises FY19 Galafold Revenue Guidance
November 11, 2019 7:02 AM ESTAmicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.24), $0.08 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $43.17 million versus the consensus estimate of $47.66 million.
John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, The third quarter represented another consecutive period of significant growth and adoption for Galafold across all geographies, as well as continued momentum in our Pompe pivotal study and our gene therapy pipeline. We are on... More
